Article
Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.
The Journal of infectious diseases - 15 May 2007
Beernink Peter T, Welsch Jo Anne, Harrison Lee H, Leipus Arunas, Kaplan Sheldon L, Granoff Dan M
Abstract excerpt
BACKGROUND: Two promising recombinant meningococcal protein vaccines are in development. One contains factor H-binding protein (fHBP) variants (v.) 1 and 2, whereas the other contains v.1 and 4 other antigens discovered by genome mining (5 component [5C]). Antibodies against fHBP are bactericidal against strains within a variant group. There are limited data on the prevalence of strains expressing different fHBP...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.